Therefore, we investigated the prospective value of assessing CIP2A and related proteins at diagnosis in a subset of 172 patients enrolled in the United Kingdom SPIRIT2 trial, a phase 3 study comparing imatinib and dasatinib for first-line treatment in newly diagnosed chronic-phase CML patients. The gene discussed is CIP2A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.